Author:
Carrato Alfredo,Abad Albert,Massuti Bartomeu,Grávalos Cristina,Escudero Pilar,Longo-Muñoz Federico,Manzano José-Luis,Gómez Auxiliadora,Safont María José,Gallego Javier,García-Paredes Beatriz,Pericay Carles,Dueñas Rosario,Rivera Fernando,Losa Ferrán,Valladares-Ayerbes Manuel,González Encarnación,Aranda Enrique
Reference34 articles.
1. Panitumumab–FOLFOX4 treatment and RAS mutations in colorectal cancer;Douillard;N Engl J Med,2013
2. PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer
3. Abad A, Massuti B, Grávalos C, et al. Phase II trial of panitumumab plus FOLFOX4 or FOLFIRI in subjects with KRAS wild-type colorectal cancer and liver-limited disease: The PLANET study. Poster presented at the ASCO 50th Annual Meeting, May 30-June 3, 2014, Chicago, IL; Abstract # 3560 and Poster. Available at:: http://meetinglibrary.asco.org/content/97302?format=posterImg&poster=1. [Accessed 14 November 2016].
4. Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer;Karthaus;Br J Cancer,2016
5. NCCN Clinical Practice Guidelines In Oncology: Colon Cancer v.2.2016. Available at:: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. [Accessed 14 November 2016].
Cited by
69 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献